Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CING | US
0.42
6.53%
Healthcare
Biotechnology
30/06/2024
09/03/2026
6.85
6.29
7.00
6.20
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
74.2%1 month
76.0%3 months
86.8%6 months
74.1%-
-
4.53
0.11
0.06
-0.36
-
-
-18.05M
20.85M
20.85M
-
-
-
-
-1.36K
0.05
0.95
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.40
Range1M
2.39
Range3M
4.17
Rel. volume
1.24
Price X volume
2.86M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| iBio Inc | IBIO | Biotechnology | 2.5 | 22.84M | -4.21% | n/a | 20.92% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 7.025 | 22.45M | 0.64% | n/a | 14.63% |
| DOMH | DOMH | Biotechnology | 3.21 | 20.15M | 7.72% | n/a | 7.66% |
| JSPR | JSPR | Biotechnology | 1.31 | 19.79M | -5.07% | n/a | 2.31% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.8002 | 19.19M | 1.27% | n/a | 0.00% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.87 | 19.07M | 1.08% | n/a | 2.12% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.89 | 18.85M | 0.53% | n/a | 3.49% |
| NRXP | NRXP | Biotechnology | 1.73 | 18.60M | 1.76% | n/a | -46.73% |
| IO Biotech Inc. Common Stock | IOBT | Biotechnology | 0.28 | 18.45M | -6.82% | n/a | 2.23% |
| PLUR | PLUR | Biotechnology | 3.37 | 18.43M | 2.74% | n/a | 30845.83% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.53 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 86.83 | 72.80 | Par |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 20.85M | 3.66B | Emerging |